70% of classic homocystinuria patients are unhappy with their treatment (MARKETVUE® REPORT)
Drug development for homocystinuria is limited to just three clinical-stage products, two of which are injectable enzyme replacement therapies (ERTs). NEWTON, Mass., April 11, 2023 /PRNewswire/ -- Classic homocystinuria (HCU) is a [...]
1 in 3 pemphigoid patients not well-managed on current treatments (MARKETVUE® REPORT)
Several companies including argenx, Sanofi/Regeneron, and AstraZeneca are seeking to improve Bullous Pemphigoid standard of care by pursuing label expansions for their existing antibody-based therapies. NEWTON, Mass., March 16, 2023 /PRNewswire/ -- Bullous [...]
MARKETVUE® REPORT: 60% of ANCA-associated vasculitis U.S. clinicians report Amgen’s Tavneos’ steroid-sparing ability and remission times as impressive
AdComm experts were split on whether to approve Amgen's Tavneos (avacopan) in 2021, however, this sentiment has not been reflected in physician uptake and perception of Tavneos which has been [...]
MARKETVUE® REPORT: Frontal Fibrosing Alopecia burden of disease is significant with half of patients unable to achieve complete response to treatment
According to REACH Market Research, dermatologists agree that Frontal Fibrosing Alopecia (FFA) is generally more difficult to treat, and less likely to have an optimal response to treatment than Alopecia Areata [...]
70% of classic homocystinuria patients are unhappy with their treatment (MARKETVUE® REPORT)
Drug development for homocystinuria is limited to just three clinical-stage products, two of which are injectable enzyme replacement therapies (ERTs). NEWTON, Mass., April 11, 2023 /PRNewswire/ -- Classic homocystinuria (HCU) is a [...]
1 in 3 pemphigoid patients not well-managed on current treatments (MARKETVUE® REPORT)
Several companies including argenx, Sanofi/Regeneron, and AstraZeneca are seeking to improve Bullous Pemphigoid standard of care by pursuing label expansions for their existing antibody-based therapies. NEWTON, Mass., March 16, 2023 /PRNewswire/ -- Bullous [...]
MARKETVUE® REPORT: 60% of ANCA-associated vasculitis U.S. clinicians report Amgen’s Tavneos’ steroid-sparing ability and remission times as impressive
AdComm experts were split on whether to approve Amgen's Tavneos (avacopan) in 2021, however, this sentiment has not been reflected in physician uptake and perception of Tavneos which has been [...]
MARKETVUE® REPORT: Frontal Fibrosing Alopecia burden of disease is significant with half of patients unable to achieve complete response to treatment
According to REACH Market Research, dermatologists agree that Frontal Fibrosing Alopecia (FFA) is generally more difficult to treat, and less likely to have an optimal response to treatment than Alopecia Areata [...]